Yes, indeed, Anavex has very thoroughly explained the blarcamesine mechanism of action (MOA), along with data from Phase 1 and 2 clinical trial outcomes of wonderful safety and efficacies.
And, yes, it is as Anavex has explained it. But market forces don’t believe it; haven’t yet decided to act on all of what Anavex has revealed. Anyone, a retail equity investor, or an institution can spend an afternoon scrutinizing all of the data on the Anavex webpages. The company isn’t hiding anything; it’s all laid out in the charts and graphics. But, so far, without Phase 3 clinical trial readouts, very few believe that the preliminary data will result in positive Phase 3 outcomes. They are going to wait to see; not ready to make any AVXL commitment from what they see in the existing data.